FI76888B - Nya medel och foerpackningar foer immunologiska analyser. - Google Patents
Nya medel och foerpackningar foer immunologiska analyser. Download PDFInfo
- Publication number
- FI76888B FI76888B FI821441A FI821441A FI76888B FI 76888 B FI76888 B FI 76888B FI 821441 A FI821441 A FI 821441A FI 821441 A FI821441 A FI 821441A FI 76888 B FI76888 B FI 76888B
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- solid support
- antigens
- antibodies
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims description 145
- 102000036639 antigens Human genes 0.000 claims description 143
- 108091007433 antigens Proteins 0.000 claims description 143
- 210000002966 serum Anatomy 0.000 claims description 74
- 108060003951 Immunoglobulin Proteins 0.000 claims description 59
- 102000018358 immunoglobulin Human genes 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 229940072221 immunoglobulins Drugs 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 30
- 239000000020 Nitrocellulose Substances 0.000 claims description 27
- 229920001220 nitrocellulos Polymers 0.000 claims description 27
- 230000000903 blocking effect Effects 0.000 claims description 24
- 238000001179 sorption measurement Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 208000025747 Rheumatic disease Diseases 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000000552 rheumatic effect Effects 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 10
- 229920003023 plastic Polymers 0.000 claims description 10
- 238000010324 immunological assay Methods 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 9
- 238000011002 quantification Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 108010069112 Complement System Proteins Proteins 0.000 claims description 6
- 102000000989 Complement System Proteins Human genes 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000003269 fluorescent indicator Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 229920002492 poly(sulfone) Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 238000006073 displacement reaction Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 241001430197 Mollicutes Species 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000011160 research Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 description 50
- 238000003018 immunoassay Methods 0.000 description 23
- 238000010790 dilution Methods 0.000 description 22
- 239000012895 dilution Substances 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 22
- 241000283073 Equus caballus Species 0.000 description 20
- 238000009739 binding Methods 0.000 description 19
- 230000027455 binding Effects 0.000 description 17
- 102000003992 Peroxidases Human genes 0.000 description 16
- 108040007629 peroxidase activity proteins Proteins 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 241000283707 Capra Species 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 201000006747 infectious mononucleosis Diseases 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108010015776 Glucose oxidase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- -1 aliphatic alcohols Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 241000287531 Psittacidae Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000001768 subcellular fraction Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010037688 Q fever Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150078635 18 gene Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 240000006122 Chenopodium album Species 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 244000026839 Juglans californica Species 0.000 description 1
- 235000014053 Juglans californica Nutrition 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
- OZBZONOEYUBXTD-UHFFFAOYSA-N OOOOOOOOO Chemical compound OOOOOOOOO OZBZONOEYUBXTD-UHFFFAOYSA-N 0.000 description 1
- UIQWBVPFHHQZHH-UHFFFAOYSA-N OOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOO UIQWBVPFHHQZHH-UHFFFAOYSA-N 0.000 description 1
- VAZNCFOEOCSGQL-UHFFFAOYSA-N OOOOOOOOOOOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOOOOOOOOOOO VAZNCFOEOCSGQL-UHFFFAOYSA-N 0.000 description 1
- PWTOMWQKTVMNMM-UHFFFAOYSA-N OOOOOOOOOOOOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOOOOOOOOOOOO PWTOMWQKTVMNMM-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000209466 Platanus Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000475042 Stolonifera Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241001149163 Ulmus americana Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001069 large ribosome subunit Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (23)
1. Medel för att utfÖra immunologiska analyser, vilket medel omfattar ett poröst, fast stödmaterial bildat av na-turliga polymera kolhydrater eller syntetiskt modifierade, tvärbundna eller substituerade derivat därav eller av poly-amid eller polysulfonkopolymer, kännetecknat därav, att man har grupperat däri pa förutbestämt sätt anti-gener och/eller immunoglobuliner pi begränsade adsorptionsom-raden, vilka föreningar fäster hlrt och sprider sig inte pa den porösa ytan, och vilka omraden är erhälinä genom att lös-nings- eller suspensionsandelar av dessa immunoreaktiva föreningar bringas i direkt kontakt med stödmaterialet genom mekanisk förflyttning, och att i det porösa fasta stödmate-rialet förekommande överskottsadsorptionspunkter eventuellt mättas med proteiner, vilka inte har specifik kapacitet att reagera med de nämnda immunoreaktiva föreningarna.
2. Medel enligt patentkravet 1, kännetecknat därav, att överskottsadsorptionspunkterna mättas med helse-rum eller med fysiologisk saltlösning eller med nagot annat, med ett lösningsmedel utspätt helserum, vid en temperatur, som är mellan rumstemperatur och ca 50 °C, och att stödmate-rialet eventuellt torkas och/eller det upphettas vid förhöjd temperatur.
3. Medel enligt patentkravet 1, kännetecknat därav, att de immunoreaktiva föreningarna är antigener, vilka är mänskligt provbitmaterial, däggdjursvävnader eller celler, kroppsvätskor, fungi, protozoa, metazoaparasiter, 68 768 8 8 bakterier, mycoplasma, virus eller preparat av dessa.
4. Medel enligt patentkravet 1, kännetecknat därav, att det porösa fasta stödmaterialet är i form av en skiva.
5. Medel enligt patentkravet 4,kännetecknat därav, att skivans tjocklek är mellan ca 0,01 - 0,5 mm.
6. Medel enligt patentkravet 4, kännetecknat därav, att skivans tjocklek är ca 0,1 mm.
7. Medel enligt patentkravet 1, kännetecknat därav, att det porösa fasta stödmaterialet är en cellulosa-ester av salpetersyra eller en alifatisk karboxylsyra med 1-7 kolatomer, eller en blandning av sädana estrar.
8. Medel enligt patentkravet 7, kännetecknat därav, att det porösa fasta stödmaterialet är nitrocellulose.
9. Medel enligt patentkravet 8, kännetecknat därav, att det porösa fasta stödmaterialet är en nitrocellu-losaskiva med porstorlek av ca 0,45 /um.
10. Medel enligt patentkravet 1, kännetecknat därav, att de förutbestämda adsorptionsomradena är i form av mikropunkter, vars diameter är under 2 mm eller i form av linjer, vars bredd är 2 mm eller mindre.
11. Medel enligt patentkravet 1, kännetecknat därav, att det förutbestämda adsorptionsomradet om-fattar en enda punkt.
12. Medel enligt patentkravet 1, kännetecknat därav, att de immunoreaktiva föreningarna har till-förts det porösa fasta stödmaterialet genom pipettering för hand eller mekaniskt eller med hjälp av flytande eller gas-formiga drivmedel.
13. Medel enligt patentkravet 1, kännetecknat därav, att de immunoreaktiva föreningarna är immu-noglobuliner eller dess fragment av mänskligt eller animalt ursprung, vilka är avsedda för detektering och kvantifiering av reumatisk faktor.
14. Medel enligt patentkravet 1, kännetecknat därav, att den immunoreaktiva föreningen är ett komp- 69 76888 lementprotein avsett för detektering av sasom cirkulerande immunokomplexer kända antigen-antikropp-komplexer.
15. Förpackning för att utföra en immunologisk analys, vilken förpackning innehaller ett poröst fast stödmaterial, apparatur för att utföra de immunologiska reaktionerna och reagenser för ett indikatorsystem i uppdelad eller i torkad form, kännetecknad därav, att det porösa fasta stödmaterialet är ett medel enligt nagot av patentkraven 1-14.
16. Förpackning enligt patentkravet 15, kännetecknad därav, att reagenserna för indikatorsystemet är (a) en radioaktivt märkt antikropp, en antikropp, som konju-gerats med en fluorescerande indikator eller en antikropp, som konjugerats med ett enzym, som ger en färgreaktion med ett lämpligt substrat, eller (b) en antikropp och ett radioaktivt märkt eller med en fluorescerande indikator eller ett enzym konjugerat komple-mentprotein, eller (c) en antikropp, ett komplementprotein och en komplement-specifik antikropp, som är radioaktivt märkt eller konjuge-rad med en fluorescerande indikator eller ett enzym.
17. Förpackning enligt patentkravet 15, kännetecknad därav, att apparaturen för att utföra de immu-nologiska reaktionerna utgör en plastbricka med flera för-djupningar och att reagenserna för indikatorsystemet utgör en lyofiliserad blandning, som innehaller en enzymkonjugerad antikropp, salter, buffertar och bärserum eller bärprotein, en lyofiliserad blandning, som innehaller förutbestämda mängder av ett kromogent substrat för enzymet, salter och buffertar, och ampuller, som innehaller förutbestämda voly-mer av flytande enzymsubstrat.
18. Förpackning enligt patentkravet 15, kännetecknad därav, att det porösa fasta stödmaterialet innehaller grupperat en eller flera specifika antikroppar och att reagenserna för indikatorsystemet innehaller ett 70 7 6888 substrat, en kofaktor eller en prostetisk grupp för ett in-dikatorenzym eller en kopplad enzymserie, som signalerar antigen-antikroppreaktionen, eller signalsystemet är ett ko-valent enzym-antigenaddukt.
19. Förpackning enligt patentkravet 18, kanne-t e c k n a d därav, att det porösa fasta stödmaterialet innehaller grupperat en eller flera specifika antikroppar tillsammans med ett indikatorenzym eller en kopplad enzymserie.
20. Förpackning enligt patentkravet 15, känne-t e c k n a d därav, att det porösa fasta stödmaterialet innehaller grupperat immunoglobuliner eller dess fragment av mänskligt eller animalt ursprung, avsedda för detektering och kvantifiering av reumatisk faktor, eller grupperat ett komplementprotein, som är avsett för detektering av antigen-ant ikroppkomplex, kSnda som cirkulerande immunkomplex.
21. Användning av ett medel eller en förpackning enligt nagot av patentkraven 1-20 för detektering och kvantifiering av specifika antigener och/eller specifika antikroppar me-delst immunmetoder, för diagnosticering, uppföljning eller prognosticering av sjukdomar hos mSnniskor och djur, eller i forsknings- och utvecklingsarbete avseende de nSmnda anti-generna eller antikropparna.
22. Förfarande för framställning av ett medel enligt nagot av patentkraven 1-14, kännetecknat därav, att lösnings- eller suspensionsandelar av antigener och/eller immunoglobuliner bringas i direkt kontakt med det porösa fasta stödmaterialet genom mekanisk förflyttning för att bilda en förutbestämd gruppering, och, om sa önskas, det sa erhall-na medlet behandlas med proteiner, som inte har specifik ka-pacitet att reagera med de nämnda immunoreaktiva föreningar-na, för att matta överskottsadsorptionspunkterna i det porösa fasta stödmaterialet.
23. Metod för immunologisk analys, känneteck-n a d därav, att ett medel enligt nagot av patentkraven 1-14, efter behandling pS lämpligt sätt med en blockerande lös-
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8113167 | 1981-04-29 | ||
| GB8113167 | 1981-04-29 | ||
| GB8134353 | 1981-11-13 | ||
| GB8134353 | 1981-11-13 | ||
| GB8201289 | 1982-01-18 | ||
| GB8201289 | 1982-01-18 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI821441A0 FI821441A0 (fi) | 1982-04-26 |
| FI821441L FI821441L (fi) | 1982-10-30 |
| FI76888B true FI76888B (fi) | 1988-08-31 |
| FI76888C FI76888C (sv) | 1988-12-12 |
Family
ID=27261173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI821441A FI76888C (sv) | 1981-04-29 | 1982-04-26 | Nya medel och förpackningar för immunologiska analyser. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5486452A (sv) |
| EP (1) | EP0063810B1 (sv) |
| AR (1) | AR231590A1 (sv) |
| AU (1) | AU560790B2 (sv) |
| BR (1) | BR8202492A (sv) |
| CA (1) | CA1200761A (sv) |
| CY (1) | CY1437A (sv) |
| DE (1) | DE3269567D1 (sv) |
| DK (1) | DK160336C (sv) |
| ES (3) | ES8400199A1 (sv) |
| FI (1) | FI76888C (sv) |
| GB (1) | GB2099578B (sv) |
| GR (1) | GR75430B (sv) |
| HK (1) | HK53888A (sv) |
| IE (1) | IE53295B1 (sv) |
| IL (1) | IL65627A (sv) |
| MX (1) | MX160043A (sv) |
| NO (1) | NO161347C (sv) |
| NZ (1) | NZ200443A (sv) |
| PH (1) | PH26773A (sv) |
| PT (1) | PT74816B (sv) |
| SG (1) | SG25288G (sv) |
Families Citing this family (228)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| GB2124231B (en) * | 1982-05-24 | 1985-10-02 | Corning Glass Works | Solid phase reagent for immunoassay |
| GB2125547B (en) * | 1982-07-31 | 1986-04-23 | Mochida Pharm Co Ltd | Simultaneous immunoassay of two or more substances |
| US4591570A (en) * | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
| US4666866A (en) * | 1983-04-19 | 1987-05-19 | Krauth Gary H | Immunoassay for antigens employing supported binder |
| AU2706384A (en) * | 1983-05-06 | 1984-11-08 | Monoclonal Antibodies Inc. | Colorimetric immunoassay on solid surface |
| JPS6035263A (ja) * | 1983-08-05 | 1985-02-23 | Wako Pure Chem Ind Ltd | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
| JPS6039564A (ja) * | 1983-08-12 | 1985-03-01 | Fuji Photo Film Co Ltd | 免疫反応試薬 |
| US4743560A (en) * | 1984-03-26 | 1988-05-10 | Becton Dickinson And Company | Solid phase assay |
| DE3416933A1 (de) * | 1984-05-04 | 1985-11-07 | Dora 1000 Berlin Köhler | Mit antigenen oder antikoerpern beschichteter traeger |
| US4647544A (en) * | 1984-06-25 | 1987-03-03 | Nicoli David F | Immunoassay using optical interference detection |
| EP0170746A1 (en) * | 1984-08-07 | 1986-02-12 | Covalent Technology Corporation | Biologically active material test |
| FR2569478B1 (fr) * | 1984-08-23 | 1987-01-09 | Guerin Bernard | Bandelette d'analyse immunologique et procede pour sa fabrication |
| ATE106565T1 (de) * | 1984-10-31 | 1994-06-15 | Alcon Lab Inc | Sandwich-immunotestverfahren für antigene bei ophthalmischen störungen. |
| FR2576418B1 (fr) * | 1985-01-24 | 1988-04-01 | Ambroise Thomas Pierre | Nouveau support pour tests biologiques in vitro et applications de ce support |
| FI860249A (fi) * | 1985-02-28 | 1986-08-29 | Becton Dickinson Co | Apparat och foerfarande foer flerfaldigt, samtidigt prov. |
| US5879881A (en) * | 1985-04-04 | 1999-03-09 | Hybritech, Incorporated | Solid phase system for use in ligand-receptor assays |
| JPS61247965A (ja) * | 1985-04-25 | 1986-11-05 | Susumu Kogyo Kk | 酵素免疫測定法 |
| US4900663A (en) * | 1985-09-13 | 1990-02-13 | Environmental Diagnostics, Inc. | Test kit for determining the presence of organic materials and method of utilizing same |
| TW203120B (sv) * | 1985-10-04 | 1993-04-01 | Abbott Lab | |
| DE3686474T2 (de) * | 1985-10-11 | 1993-02-11 | Abbott Lab | Diagnostische probe. |
| US6265176B1 (en) * | 1985-10-29 | 2001-07-24 | Cordis Corporation | Dot immunoassay on plastic sheets |
| US5160701A (en) * | 1986-02-18 | 1992-11-03 | Abbott Laboratories | Solid-phase analytical device and method for using same |
| KR960016340B1 (ko) * | 1986-04-30 | 1996-12-09 | 이겐 인코오포레이팃드 | 전기화학발광 분석법 |
| EP0246643A3 (en) * | 1986-05-20 | 1988-06-01 | DNA PLANT TECHNOLOGY OPERATING CO. (under the laws of the State of Delaware) | Method of preparing diagnostic test dipsticks |
| AU7385687A (en) * | 1986-06-09 | 1987-12-10 | Ortho Diagnostic Systems Inc. | Immunoglobulin immunoassay with internalized control assays |
| DE3722273A1 (de) * | 1986-07-08 | 1988-01-21 | Bio Rad Laboratories | Festphasen-bindungsreagentien, ihre herstellung und sie enthaltende assay-kits |
| US5260193A (en) * | 1986-09-05 | 1993-11-09 | Syntex (U.S.A.) Inc. | Immunoseparating strip |
| US5260194A (en) * | 1986-09-05 | 1993-11-09 | Syntex (U.S.A.) Inc. | Immunoseparating strip |
| US4960691A (en) * | 1986-09-29 | 1990-10-02 | Abbott Laboratories | Chromatographic test strip for determining ligands or receptors |
| US5126240A (en) * | 1986-09-29 | 1992-06-30 | Curtiss Linda K | Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i |
| EP0264804B1 (de) * | 1986-10-23 | 1993-08-04 | BEHRINGWERKE Aktiengesellschaft | Bioaffine poröse Festphasen, ein Verfahren zur Herstellung von bioaffinen porösen Festphasen und ihre Verwendung |
| DE3645090C2 (sv) * | 1986-10-23 | 1991-05-23 | Behringwerke Ag, 3550 Marburg, De | |
| GB2206964B (en) * | 1986-12-04 | 1991-04-24 | David Michael Kemeny | Solid phase immunoassay |
| US4829010A (en) * | 1987-03-13 | 1989-05-09 | Tanox Biosystems, Inc. | Immunoassay device enclosing matrixes of antibody spots for cell determinations |
| IT1206777B (it) * | 1987-04-06 | 1989-05-03 | Chemetron Del Dr Del Campo Gio | Procedimento di analisi immunologica o chimica per la determinazione di proteine in fluidi biologici e relativo completo (kit) di mezzi analitici. |
| US5100777A (en) * | 1987-04-27 | 1992-03-31 | Tanox Biosystems, Inc. | Antibody matrix device and method for evaluating immune status |
| ATE195022T1 (de) * | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
| CA1313616C (en) * | 1987-06-01 | 1993-02-16 | Robert B. Sargeant | Lateral flow, non-bibulous membrane protocols |
| US4880750A (en) * | 1987-07-09 | 1989-11-14 | Miragen, Inc. | Individual-specific antibody identification methods |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US6004766A (en) * | 1987-07-28 | 1999-12-21 | Biotechnology Australia Pty Limited | Method for detecting low levels of microorganisms |
| EP0301141A1 (en) * | 1987-07-30 | 1989-02-01 | Microbiological Research Corporation | Solid phase enzyme immunoassay test apparatus and process for detecting antibodies |
| US5447837A (en) * | 1987-08-05 | 1995-09-05 | Calypte, Inc. | Multi-immunoassay diagnostic system for antigens or antibodies or both |
| GB8803000D0 (en) * | 1988-02-10 | 1988-03-09 | Ekins Roger Philip | Determination of ambient concentrations of several analytes |
| US5807755A (en) * | 1987-08-06 | 1998-09-15 | Multilyte Limited | Determination of ambient concentrations of several analytes |
| US5039604A (en) * | 1987-08-21 | 1991-08-13 | Cellular Products, Inc. | Test device and method of preparing same, assay kit and method for the simultaneous detection of two HTLV or HIV antibodies |
| US4921809A (en) * | 1987-09-29 | 1990-05-01 | Findley Adhesives, Inc. | Polymer coated solid matrices and use in immunoassays |
| US5571667A (en) * | 1987-10-01 | 1996-11-05 | Chu; Albert E. | Elongated membrane flow-through diagnostic device and method |
| EP0319686A3 (en) * | 1987-10-21 | 1991-04-24 | Mochida Pharmaceutical Co., Ltd. | Method for assaying a target substance in a minute amount of nipple discharge and device for such an assay |
| DE3735684A1 (de) * | 1987-10-22 | 1989-05-03 | Boehringer Mannheim Gmbh | Immunreaktives traegermaterial und verfahren zu seiner herstellung |
| JPH01223352A (ja) * | 1988-01-11 | 1989-09-06 | General Biometrics Inc | 固相酵素免疫検定システムおよび方法 |
| DK70488D0 (da) * | 1988-02-11 | 1988-02-11 | Ancos Aps | Fremgangsmaade til paavisning af antistoffer i blod, samt membran og test-saet til anvendelse ved udoevelse af fremgangsmaaden |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US7811751B2 (en) | 1988-05-03 | 2010-10-12 | Oxford Gene Technology Limited | Analysing polynucleotide sequences |
| US20050032048A1 (en) * | 1988-05-03 | 2005-02-10 | Oxford Gene Technology Limited | Analyzing polynucleotide sequences |
| US5620845A (en) * | 1988-06-06 | 1997-04-15 | Ampcor, Inc. | Immunoassay diagnostic kit |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| CA1335880C (en) * | 1988-07-14 | 1995-06-13 | Thomas P. O'connor | Detection of an antibody and antigen in an immunoassay |
| US5075077A (en) | 1988-08-02 | 1991-12-24 | Abbott Laboratories | Test card for performing assays |
| ES2088879T3 (es) * | 1988-08-02 | 1996-10-01 | Abbott Lab | Analizador de muestras biologicas. |
| US5320808A (en) * | 1988-08-02 | 1994-06-14 | Abbott Laboratories | Reaction cartridge and carousel for biological sample analyzer |
| US5281540A (en) * | 1988-08-02 | 1994-01-25 | Abbott Laboratories | Test array for performing assays |
| US5059522A (en) * | 1988-08-18 | 1991-10-22 | Wayne Lawrence G | Intrinsic enzyme dot blot immunoassay or indentification of microorganisms |
| DE69006126T2 (de) * | 1989-02-03 | 1994-08-18 | Cetus Oncology Corp | Nukleinsäureprüfungswerkstoff und seine anwendung für die detektion einer vorausbestimmten nukleinsäure. |
| US5120662A (en) * | 1989-05-09 | 1992-06-09 | Abbott Laboratories | Multilayer solid phase immunoassay support and method of use |
| AU637097B2 (en) * | 1989-05-09 | 1993-05-20 | Abbott Laboratories | Process for preparing an improved western blot immunoassay |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6309822B1 (en) | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5925525A (en) * | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US6919211B1 (en) * | 1989-06-07 | 2005-07-19 | Affymetrix, Inc. | Polypeptide arrays |
| US6955915B2 (en) * | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
| US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US6379895B1 (en) | 1989-06-07 | 2002-04-30 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
| US6551784B2 (en) | 1989-06-07 | 2003-04-22 | Affymetrix Inc | Method of comparing nucleic acid sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| CA2025474A1 (en) * | 1989-09-27 | 1991-03-28 | Donald I. Stimpson | Hydrophilic laminated porous membranes and methods of preparing same |
| CA2025475A1 (en) * | 1989-09-27 | 1991-03-28 | Donald I. Stimpson | Hydrophilic laminated porous membranes and methods of preparing same |
| CA2025476A1 (en) * | 1989-09-27 | 1991-03-28 | Shan F. Ching | Hydrophilic laminated porous membranes and methods of preparing same |
| US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
| KR910014706A (ko) * | 1990-01-10 | 1991-08-31 | 원본미기재 | 세척이 필요없는 개량된 이뮤노어세이(immunoassay)장치 |
| KR910014705A (ko) * | 1990-01-10 | 1991-08-31 | 원본미기재 | 세척이 필요없은 딥스틱(Dipstick) 형태의 이뮤노어세이(Immunoasssay)장치 |
| US6506558B1 (en) | 1990-03-07 | 2003-01-14 | Affymetrix Inc. | Very large scale immobilized polymer synthesis |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| US5100626A (en) * | 1990-05-24 | 1992-03-31 | Levin Andrew E | Binding assay device with removable cassette and manifold |
| IE76732B1 (en) * | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
| EP0834576B1 (en) * | 1990-12-06 | 2002-01-16 | Affymetrix, Inc. (a Delaware Corporation) | Detection of nucleic acid sequences |
| US5877028A (en) | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
| US5998220A (en) | 1991-05-29 | 1999-12-07 | Beckman Coulter, Inc. | Opposable-element assay devices, kits, and methods employing them |
| US5468648A (en) | 1991-05-29 | 1995-11-21 | Smithkline Diagnostics, Inc. | Interrupted-flow assay device |
| ATE191792T1 (de) * | 1991-09-16 | 2000-04-15 | Abbott Lab | Verfahren zur detektion von hepatitis c |
| US5399484A (en) * | 1991-10-08 | 1995-03-21 | Eastman Kodak Company | Use of blocking protein with high pH extraction in method to determine a microorganism associated with periodontal disease and kit useful therefor |
| US6468740B1 (en) | 1992-11-05 | 2002-10-22 | Affymetrix, Inc. | Cyclic and substituted immobilized molecular synthesis |
| DE69233087T2 (de) | 1991-11-22 | 2003-12-24 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verfahren zur Herstellung von Polymerarrays |
| US6943034B1 (en) * | 1991-11-22 | 2005-09-13 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US6100099A (en) * | 1994-09-06 | 2000-08-08 | Abbott Laboratories | Test strip having a diagonal array of capture spots |
| EP0653065B1 (en) * | 1992-08-03 | 2002-10-30 | Marconi Optical Components Limited | Separation method |
| FI92882C (sv) * | 1992-12-29 | 1995-01-10 | Medix Biochemica Ab Oy | Testremsa för engångsbruk samt förfarande för dess framställning |
| US5558869A (en) | 1992-12-30 | 1996-09-24 | University Of Arkansas | Major peanut allergen ara h II |
| KR100338319B1 (ko) * | 1993-09-08 | 2002-11-14 | 머크 파텐트 게엠베하 | 세포시약및검정방법 |
| US5770389A (en) * | 1993-09-27 | 1998-06-23 | Abbott Laboratories | Apparatus and method for determining the quanity of an analyte in a biological sample by means of transmission photometry |
| IL108377A0 (en) * | 1994-01-19 | 1994-04-12 | Orgenics Ltd | Automated analysis with comb-like analyte support |
| US6015880A (en) * | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| DE69527585T2 (de) * | 1994-06-08 | 2003-04-03 | Affymetrix, Inc. | Verfahren und Vorrichtung zum Verpacken von Chips |
| US6287850B1 (en) * | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
| US7323298B1 (en) | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
| US7615368B1 (en) * | 1994-06-17 | 2009-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Microarrays of polypeptides |
| US8236493B2 (en) * | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
| AU4770296A (en) * | 1995-03-27 | 1996-10-16 | Warner-Lambert Company | Method and apparatus for simultaneously testing a plurality of compounds to detect their activity |
| US5922534A (en) * | 1995-03-28 | 1999-07-13 | Hewlett-Packard Company | Dry biochemical assay plate and method for making the same |
| US20010051350A1 (en) | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
| US6720149B1 (en) * | 1995-06-07 | 2004-04-13 | Affymetrix, Inc. | Methods for concurrently processing multiple biological chip assays |
| US20030202980A1 (en) * | 1995-12-29 | 2003-10-30 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US5874216A (en) | 1996-02-23 | 1999-02-23 | Ensys Environmental Products, Inc. | Indirect label assay device for detecting small molecules and method of use thereof |
| US5932430A (en) * | 1996-05-09 | 1999-08-03 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
| US5716791A (en) * | 1996-05-09 | 1998-02-10 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
| FR2750505B1 (fr) * | 1996-06-27 | 1998-10-16 | Appligene Oncor | Procede de preparation de supports d'analyse de substances chimiques ou biologiques presentant un ensemble ordonne de zones de reaction |
| US6582921B2 (en) * | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
| US5804384A (en) * | 1996-12-06 | 1998-09-08 | Vysis, Inc. | Devices and methods for detecting multiple analytes in samples |
| AU6646398A (en) | 1996-12-31 | 1998-07-31 | Genometrix Incorporated | Multiplexed molecular analysis apparatus and method |
| US5879951A (en) | 1997-01-29 | 1999-03-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
| CZ297165B6 (cs) | 1997-04-21 | 2006-09-13 | Randox Laboratories Ltd. A British Company Of Ardmore | Zpusob výroby zarízení s pevnou fází k provádení multianalytních rozboru |
| US5939252A (en) | 1997-05-09 | 1999-08-17 | Lennon; Donald J. | Detachable-element assay device |
| US5976813A (en) * | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
| US20030039967A1 (en) * | 1997-12-19 | 2003-02-27 | Kris Richard M. | High throughput assay system using mass spectrometry |
| US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
| US20100105572A1 (en) * | 1997-12-19 | 2010-04-29 | Kris Richard M | High throughput assay system |
| AU740830B2 (en) * | 1998-01-29 | 2001-11-15 | Glaucus Proteomics B.V. | High density arrays for proteome analysis and methods and compositions therefor |
| ATE430199T1 (de) * | 1998-01-31 | 2009-05-15 | Univ Arkansas | Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie |
| US7879977B2 (en) | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
| CA2318175A1 (en) | 1998-02-04 | 1999-08-12 | Invitrogen Corporation | Microarrays and uses therefor |
| US7282240B1 (en) * | 1998-04-21 | 2007-10-16 | President And Fellows Of Harvard College | Elastomeric mask and use in fabrication of devices |
| WO1999058976A1 (de) * | 1998-05-12 | 1999-11-18 | Virofem Diagnostika Gmbh | Indikationsstreifen zum nachweis von antikörpern im blutserum |
| US6545264B1 (en) | 1998-10-30 | 2003-04-08 | Affymetrix, Inc. | Systems and methods for high performance scanning |
| US7297554B2 (en) * | 1998-11-18 | 2007-11-20 | Microdiagnostics, Inc. | Immunoassay system |
| EP1159615A2 (en) * | 1999-03-10 | 2001-12-05 | National Institutes of Health, as represented by the Secretary, Department of Health and Human Services of the Government | Universal protein array system |
| AU3750000A (en) * | 1999-03-15 | 2000-10-04 | Eos Biotechnology, Inc. | Reusable low fluorescent plastic biochip |
| DE60000583T3 (de) | 1999-05-19 | 2009-04-30 | Eppendorf Array Technologies | Verfahren zur identifizierung und/oder quantifizierung einer zielverbindung |
| EP1054259A1 (en) * | 1999-05-19 | 2000-11-22 | Remacle, José | Method for the identification of a target compound |
| US20030096321A1 (en) * | 1999-05-19 | 2003-05-22 | Jose Remacle | Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips |
| AU4289799A (en) * | 1999-06-25 | 2001-01-31 | Kyowa Medex Co., Ltd. | Immunoassay supports and immunoasssay solid phases with the use thereof |
| US6969615B2 (en) * | 1999-07-26 | 2005-11-29 | 20/20 Genesystems, Inc. | Methods, devices, arrays and kits for detecting and analyzing biomolecules |
| US7838222B2 (en) * | 1999-07-26 | 2010-11-23 | United States of America/ NIH | Methods, devices and kits for multiplex blotting of biological samples from multi-well plates |
| CA2375034C (en) * | 1999-07-26 | 2012-01-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | Method and device for analysis of biological specimens |
| US7214477B1 (en) | 1999-07-26 | 2007-05-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Layered device with capture regions for cellular analysis |
| AU6054099A (en) * | 1999-09-16 | 2001-04-17 | Immunetics, Inc. | Membrane immunoassays for detection of multiple tick-borne diseases |
| US6623936B1 (en) | 1999-09-24 | 2003-09-23 | Imgenex | Compositions and methods for improved detection and classification of neoplasms |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US20070111259A1 (en) * | 1999-10-02 | 2007-05-17 | Medarex, Inc. | Human antibodies |
| US8153367B2 (en) * | 1999-10-29 | 2012-04-10 | Perkinelmer Las, Inc. | Amplified array analysis system |
| US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
| US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| DE10006432A1 (de) * | 2000-02-14 | 2001-08-16 | Ganzimmun Inst Fuer Ganzheitli | Verfahren zum Nachweis von Helicobacter pylori in Stuhl- und Speichelproben |
| AU4365601A (en) * | 2000-03-17 | 2001-10-03 | Harvard College | Cell patterning technique |
| US20050063994A1 (en) * | 2000-04-06 | 2005-03-24 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
| WO2001066136A2 (en) * | 2000-04-06 | 2001-09-13 | Panacea Pharmaceuticals, Llc. | Microbial delivery system |
| US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
| US6673614B2 (en) | 2000-06-27 | 2004-01-06 | Cell Genesys, Inc. | Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody |
| JP2004501667A (ja) * | 2000-07-01 | 2004-01-22 | クロンディアグ チップ テヒノロギーズ ゲーエムベーハー | プローブ・アレイ上での分子相互作用の定性的および／または定量的検出方法 |
| US20060275851A1 (en) * | 2000-07-26 | 2006-12-07 | Emmert-Buck Michael R | Layered peptide/antigen arrays - for high-throughput antibody screening of clinical samples |
| WO2002012898A1 (en) * | 2000-08-04 | 2002-02-14 | University Of Pune | An improved process for preparation of immunochemical complex useful for pathogen detection and determination of their antibiotic sensitivity |
| US20040185464A1 (en) * | 2000-09-15 | 2004-09-23 | Kris Richard M. | High throughput assay system |
| AU2001292959A1 (en) * | 2000-09-22 | 2002-04-02 | Clontech Laboratories, Inc. | Highly sensitive proteomic analysis methods and kits and systems for practicing the same |
| US6528325B1 (en) * | 2000-10-13 | 2003-03-04 | Dexall Biomedical Labs, Inc. | Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays |
| US6905816B2 (en) * | 2000-11-27 | 2005-06-14 | Intelligent Medical Devices, Inc. | Clinically intelligent diagnostic devices and methods |
| US20030129680A1 (en) * | 2001-10-31 | 2003-07-10 | O'connor Thomas Patrick | Multi-analyte assay device |
| US7087389B2 (en) * | 2001-02-09 | 2006-08-08 | Council Of Scientific & Industrial Research | Highly cost-effective analytical device for performing immunoassays with ultra high sensitivity |
| EP2302391A1 (en) * | 2001-04-10 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic uses of antibody specificity profiles in rheumatoid arthritis |
| WO2003005013A1 (en) * | 2001-07-03 | 2003-01-16 | Georgia Tech Research Corporation | Filtration-based microarray chip |
| US20030013208A1 (en) * | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| US20030044869A1 (en) * | 2001-09-04 | 2003-03-06 | Yeung Jupiter M. | Method and apparatus for detecting protein in a sample |
| SE0103072D0 (sv) * | 2001-09-17 | 2001-09-17 | Pharmacia Diagnostics Ab | Multi-analyte assay device with multi-spot detection zone |
| DK1436621T3 (da) * | 2001-09-17 | 2011-04-04 | Phadia Ab | Multianalytprøveapparat med multi-punkt-detektionszone |
| DE10153963A1 (de) * | 2001-11-06 | 2003-05-22 | Aventis Behring Gmbh Intellect | Testsystem zur Untersuchung einer biologischen Flüssigkeit |
| US7141368B2 (en) * | 2002-01-30 | 2006-11-28 | Agilent Technologies, Inc. | Multi-directional deposition in array fabrication |
| US7033777B2 (en) * | 2002-03-22 | 2006-04-25 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting cockroach allergens and determining total allergen level |
| US7154598B2 (en) * | 2002-07-12 | 2006-12-26 | Decision Biomarkers, Inc. | Excitation and imaging of fluorescent arrays |
| US7384742B2 (en) * | 2002-08-16 | 2008-06-10 | Decision Biomarkers, Inc. | Substrates for isolating reacting and microscopically analyzing materials |
| US20060127946A1 (en) * | 2002-08-16 | 2006-06-15 | Montagu Jean I | Reading of fluorescent arrays |
| EP1560917A1 (en) * | 2002-11-08 | 2005-08-10 | University of Copenhagen | Method of immobilising a protein to a zeolite |
| WO2004048928A2 (en) * | 2002-11-25 | 2004-06-10 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array |
| US20040152083A1 (en) * | 2003-01-31 | 2004-08-05 | Leproust Eric M. | Multiple arrays with surface energy transition to maintain separation of samples on the arrays |
| US7935539B2 (en) * | 2003-02-14 | 2011-05-03 | Siemens Healthcare Diagnostics, Inc. | Generic method for latex agglutination assays |
| US6861251B2 (en) * | 2003-02-24 | 2005-03-01 | Pritest, Inc. | Translucent solid matrix assay device for microarray analysis |
| US20040241659A1 (en) * | 2003-05-30 | 2004-12-02 | Applera Corporation | Apparatus and method for hybridization and SPR detection |
| US20070111325A1 (en) * | 2003-11-28 | 2007-05-17 | Van Beuningen Marinus G J | Methods and devices for compound screening |
| FR2874093B1 (fr) * | 2004-08-03 | 2006-12-01 | Inodiag Sa | Methode et trousse de determination du statut vaccinal de personnes |
| GB0409771D0 (en) | 2004-04-30 | 2004-06-09 | Mabtech Ab | Assay |
| GB0409775D0 (en) | 2004-04-30 | 2004-06-09 | Mabtech Ab | Assay |
| GB2414298B (en) * | 2004-05-18 | 2008-09-10 | Michael Strachan Walker | Diagnostic method and apparatus |
| US20050277158A1 (en) * | 2004-06-10 | 2005-12-15 | Ge Chen | Method and kit for donor specific complement-fixing antibodies crossmatch |
| US7704730B2 (en) * | 2004-10-14 | 2010-04-27 | Meso Scale Technologies, Llc | Multiplexed assay methods |
| NZ554895A (en) * | 2004-11-03 | 2009-06-26 | Almac Diagnostics Ltd | Transcriptome microarray technology and methods of using the same |
| US20060115908A1 (en) * | 2004-11-30 | 2006-06-01 | Tetracore, Inc. | Multiplexed analyses of contaminant-laden gas in a particle impact collector |
| US20060154299A1 (en) * | 2005-01-08 | 2006-07-13 | Harvey Michael A | Protein microarray device having internal calibrators and methods of using therefor |
| WO2006138647A2 (en) * | 2005-06-16 | 2006-12-28 | Gtc Biotherapeutics, Inc. | Method of making recombinant human antibodies for use in biosensor technology |
| US20080008699A1 (en) * | 2005-10-28 | 2008-01-10 | Jianxun Li | Method for proteomic analysis utilizing immune recognition and cumulative subtraction |
| DE102006027259A1 (de) * | 2006-06-09 | 2007-12-13 | Protagen Ag | Protein-Biochip zum differentiellen Screenen von Protein-Protein-Wechselwirkungen |
| WO2008008284A2 (en) | 2006-07-14 | 2008-01-17 | The Regents Of The University Of California | Cancer biomarkers and methods of use threof |
| KR20080015339A (ko) * | 2006-08-14 | 2008-02-19 | 삼성전자주식회사 | 가장자리 측벽이 비활성화된 프로브 셀 액티브를 포함하는올리고머 프로브 어레이 및 그 제조 방법 |
| US8003312B2 (en) * | 2007-02-16 | 2011-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplex cellular assays using detectable cell barcodes |
| CA2694281A1 (en) * | 2007-08-13 | 2009-02-19 | Almac Diagnostics Limited | A 3'-based sequencing approach for microarray manufacture |
| US20090075828A1 (en) * | 2007-09-17 | 2009-03-19 | Gentel Biosurfaces, Inc. | Integrated protein chip assay |
| GB0718606D0 (en) * | 2007-09-24 | 2007-10-31 | Bio A R T Sa | Multiparameter assay |
| EP2294408A4 (en) * | 2008-02-21 | 2011-05-25 | Gentel Biosciences Inc | SUBSTRATES FOR MULTIPLEX TEST PROCEDURES AND USES THEREFOR |
| DE102009033008A1 (de) | 2009-07-02 | 2011-01-05 | Dst Diagnostische Systeme & Technologien Gmbh | Neues PoC-Testsystem und Verfahren |
| DE102009037791A1 (de) | 2009-08-17 | 2011-02-24 | Dst Diagnostische Systeme & Technologien Gmbh | Testsystem zur visuellen Auswertung |
| CA2684636A1 (en) | 2009-10-30 | 2011-04-30 | Sqi Diagnostics Systems Inc | Multiplex microarrays and methods for the quantification of analytes |
| EP3508854A1 (en) | 2010-04-27 | 2019-07-10 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
| EP2560004A1 (de) | 2011-08-19 | 2013-02-20 | DST Diagnostische Systeme & Technologien GmbH | Neues PoC-Testsystem und Verfahren |
| RU2495434C2 (ru) * | 2011-12-09 | 2013-10-10 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Набор для многопрофильного иммунологического анализа антител в препаратах крови |
| EP2767831A1 (de) | 2013-02-19 | 2014-08-20 | DST Diagnostische Systeme & Technologien GmbH | Neues PoC-Testsystem und Verfahren |
| KR20140111192A (ko) * | 2013-03-08 | 2014-09-18 | (주)프로테옴텍 | 다중 진단용 병렬식 라인형 바이오칩 |
| JP6670830B2 (ja) * | 2014-06-13 | 2020-03-25 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | クロマトグラフ検出パッドを使用する溶血検出 |
| EP3227687A4 (en) | 2014-12-05 | 2018-10-24 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
| RU2686490C1 (ru) * | 2018-06-01 | 2019-04-29 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Набор для мультиплексного иммунохимического анализа антител и антигенов в препаратах крови |
| AU2019339508A1 (en) | 2018-09-14 | 2021-04-15 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
| US20210293806A1 (en) * | 2018-10-23 | 2021-09-23 | Sekisui Medical Co., Ltd. | Immunochromatographic test strip |
| CN112198310B (zh) * | 2020-11-30 | 2021-03-02 | 南京申基医药科技有限公司 | 一种c反应蛋白和血清淀粉样蛋白a联合检测试纸条、试剂盒及试纸条的制备方法 |
| CN115840042B (zh) * | 2023-02-24 | 2023-04-28 | 北京凡知医学科技有限公司 | 一种免疫层析试纸盒及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO122497B (sv) * | 1967-02-16 | 1971-07-05 | Saxholm Rolf | |
| GB1235686A (en) * | 1967-02-16 | 1971-06-16 | Rolf Saxholm | Improvements in diffusion testing and apparatus therefor |
| US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| GB1329823A (en) * | 1970-06-09 | 1973-09-12 | Oxoid Ltd | Means for carrying out diagnostic tests for infections |
| US3664421A (en) * | 1970-09-18 | 1972-05-23 | Schlumberger Technology Corp | Methods for inhibiting the production of loose formation materials |
| US3666421A (en) * | 1971-04-05 | 1972-05-30 | Organon | Diagnostic test slide |
| DE2440367C2 (de) * | 1973-08-30 | 1984-03-15 | General Electric Co., Schenectady, N.Y. | Verfahren zum Herstellen multimolekularer Schichten aus immunologisch komplexierten Proteinen auf einem Substrat |
| US4176174A (en) * | 1974-07-19 | 1979-11-27 | Burroughs Wellcome Co. | Viral antibody diagnostic test system |
| US3979509A (en) * | 1974-09-03 | 1976-09-07 | General Electric Company | Opaque layer method for detecting biological particles |
| SE388694B (sv) * | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
| US4048298A (en) * | 1975-02-25 | 1977-09-13 | Rohm And Haas Company | Solid phase double-antibody radioimmunoassay procedure |
| DK137089B (da) * | 1975-05-09 | 1978-01-16 | Kai Aage Hansen | Steril indikator til brug ved udvælgelse af baktericide stoffer, samt en fremgangsmåde til fremstilling af en sådan indikator. |
| US4275053A (en) * | 1975-08-14 | 1981-06-23 | Mt. Sinai School Of Medicine Of The City University Of New York | Blood cell typing and compatibility test procedure |
| DE2638207C2 (de) * | 1975-08-27 | 1985-10-03 | General Electric Co., Schenectady, N.Y. | Verfahren zum Bilden multimolekularer immunologisch komplexierter Filme |
| DE2603319C3 (de) * | 1976-01-29 | 1979-08-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur Fixierung von biologisch aktiven Proteinen an Trägern |
| US4020151A (en) * | 1976-02-17 | 1977-04-26 | International Diagnostic Technology, Inc. | Method for quantitation of antigens or antibodies on a solid surface |
| FR2353856A1 (fr) * | 1976-06-02 | 1977-12-30 | Chateau Guy | Ruban destine a servir de support a une reaction par exemple chimique ou biochimique, et procede d'analyse le mettant en oeuvre |
| IL52322A (en) * | 1976-06-18 | 1980-10-26 | Alfa Laval Ab | Method of making reagent test device and device made accorording to this method |
| DE2755689A1 (de) * | 1976-12-16 | 1978-06-22 | Millipore Corp | Verfahren zur bestimmung der anwesenheit einer komponente einer immunchemischen reaktion und diagnostisches immunchemisches testmaterial zur durchfuehrung des verfahrens |
| US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
| US4407943A (en) * | 1976-12-16 | 1983-10-04 | Millipore Corporation | Immobilized antibody or antigen for immunoassay |
| CH620300A5 (en) * | 1977-04-29 | 1980-11-14 | Miles Lab | Reactive strip for analysis |
| US4157895A (en) * | 1977-10-07 | 1979-06-12 | Nuclear International Corporation | RIA reagents and processes |
| US4139346A (en) * | 1977-11-28 | 1979-02-13 | Enzo Bio Chem Incorporated | Nucleic acid and protein binding paper |
| US4189464A (en) * | 1978-05-05 | 1980-02-19 | Institute For Cancer Research | Hepatitis B testing reagent and method |
| US4216245A (en) * | 1978-07-25 | 1980-08-05 | Miles Laboratories, Inc. | Method of making printed reagent test devices |
| US4267270A (en) * | 1979-05-21 | 1981-05-12 | Enzyme Technology, Inc. | Method for the determination of antigens and antibodies using site-deactivating media |
| US4414324A (en) * | 1979-05-21 | 1983-11-08 | Bma Laboratory Services, Inc. | Immunoassay method and apparatus |
| US4302204A (en) * | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
| US4305720A (en) * | 1979-08-20 | 1981-12-15 | Becton Dickinson & Company | Gentamicin assay and products therefor |
| US4305721A (en) * | 1979-08-20 | 1981-12-15 | Becton Dickinson & Company | Agglutination assay |
| US4378344A (en) * | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| US4452901A (en) * | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4332283A (en) * | 1980-08-18 | 1982-06-01 | Ajay Enterprises, Inc. | Device for supporting and protecting golf clubs |
| BR8108820A (pt) * | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| US4358535A (en) * | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
| US4436824A (en) * | 1981-06-09 | 1984-03-13 | Ortho Diagnostic Systems, Inc. | Leukocyte migration through antigen containing agaroses for immunocompetence testing |
| US4459360A (en) * | 1981-10-05 | 1984-07-10 | Mast Medical Industries, Ltd. | Multiple-component binding assay system and method of making and using it |
| US4591570A (en) * | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
-
1982
- 1982-04-26 AR AR289207A patent/AR231590A1/es active
- 1982-04-26 EP EP82103520A patent/EP0063810B1/en not_active Expired
- 1982-04-26 DE DE8282103520T patent/DE3269567D1/de not_active Expired
- 1982-04-26 FI FI821441A patent/FI76888C/sv not_active IP Right Cessation
- 1982-04-27 GR GR68001A patent/GR75430B/el unknown
- 1982-04-27 IL IL65627A patent/IL65627A/xx not_active IP Right Cessation
- 1982-04-27 CA CA000401717A patent/CA1200761A/en not_active Expired
- 1982-04-27 ES ES511735A patent/ES8400199A1/es not_active Expired
- 1982-04-28 DK DK189182A patent/DK160336C/da not_active IP Right Cessation
- 1982-04-28 MX MX192469A patent/MX160043A/es unknown
- 1982-04-28 IE IE998/82A patent/IE53295B1/en not_active IP Right Cessation
- 1982-04-28 GB GB8212275A patent/GB2099578B/en not_active Expired
- 1982-04-28 NO NO821411A patent/NO161347C/no not_active IP Right Cessation
- 1982-04-28 PH PH27205A patent/PH26773A/en unknown
- 1982-04-28 NZ NZ200443A patent/NZ200443A/en unknown
- 1982-04-28 AU AU83069/82A patent/AU560790B2/en not_active Expired
- 1982-04-29 BR BR8202492A patent/BR8202492A/pt unknown
- 1982-04-29 PT PT74816A patent/PT74816B/pt unknown
-
1983
- 1983-06-30 ES ES523723A patent/ES523723A0/es active Granted
- 1983-06-30 ES ES523722A patent/ES523722A0/es active Granted
-
1987
- 1987-04-10 US US07/038,470 patent/US5486452A/en not_active Expired - Lifetime
-
1988
- 1988-04-12 SG SG252/88A patent/SG25288G/en unknown
- 1988-07-14 HK HK538/88A patent/HK53888A/xx not_active IP Right Cessation
-
1989
- 1989-03-10 CY CY1437A patent/CY1437A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI76888B (fi) | Nya medel och foerpackningar foer immunologiska analyser. | |
| US10732111B2 (en) | Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases | |
| US4020151A (en) | Method for quantitation of antigens or antibodies on a solid surface | |
| TW412637B (en) | Optical quantification of analytes in membranes | |
| US20230213510A1 (en) | Methods relating to improving accuracy of capture object-based assays | |
| US4786589A (en) | Immunoassay utilizing formazan-prelabeled reactants | |
| CN100420947C (zh) | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 | |
| US20050101031A1 (en) | Allergen-microarray assay | |
| JPH03502244A (ja) | 試験方法およびそのための試薬キツト | |
| KR20000071894A (ko) | 단백질칩 및 이를 이용한 다목적 자동화 진단시스템 | |
| CA2588420A1 (en) | Device and method for detection of analytes | |
| US20010046682A1 (en) | Dry biochemical assay plate and method for making the same | |
| EP1667780A1 (en) | Method of detecting multiple analytes | |
| JPH04500860A (ja) | 分析的アッセイ方法 | |
| JPS589070A (ja) | 免疫分析用装置及びキツト | |
| CN109781972B (zh) | 一种免疫定量检测方法和应用 | |
| JP4920173B2 (ja) | 較正マイクロアレイ | |
| JP4627607B2 (ja) | 複数項目及び総含有量の同時分析可能なイムノクロマトグラフ法及びイムノクロマトグラフ用ストリップ | |
| WO1990015328A1 (en) | Improved immunoassay | |
| US20130217015A1 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
| AU4647393A (en) | Chemiluminescent assay for dsdna antibodies | |
| RU2519023C2 (ru) | Способ детектирования концентрации аналита с широким динамическим диапазоном | |
| EP1382966A1 (en) | Microvolume detecting method and device | |
| CN118243915A (zh) | 多联荧光免疫层析检测试纸卡及检测方法 | |
| JP2004177321A (ja) | 微量検出方法及び装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: NOVARTIS AG |
|
| MA | Patent expired |
Owner name: NOVARTIS AG |